These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 32730231

  • 1. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
    Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW.
    JCI Insight; 2020 Sep 03; 5(17):. PubMed ID: 32730231
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.
    El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, Wainscott DB, Yang B, Chen A, Wothe D, Coupland C, Tschöp MH, Finan B, D'Alessio DA, Sloop KW, Müller TD, Campbell JE.
    Nat Metab; 2023 Jun 03; 5(6):945-954. PubMed ID: 37277609
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design of a novel long-acting dual GLP-1/GIP receptor agonist.
    Dong Y, Zhang J, Xu H, Shen H, Lu Q, Feng J, Cai Z.
    Bioorg Med Chem; 2024 Feb 15; 100():117630. PubMed ID: 38330849
    [Abstract] [Full Text] [Related]

  • 9. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
    Nowak M, Nowak W, Grzeszczak W.
    Endokrynol Pol; 2022 Feb 15; 73(4):745-755. PubMed ID: 35593668
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
    Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA.
    J Clin Endocrinol Metab; 2021 Jan 23; 106(2):388-396. PubMed ID: 33236115
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
    Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK.
    Diabetes Obes Metab; 2023 Nov 23; 25(11):3079-3092. PubMed ID: 37551549
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.
    Gastroenterology; 2009 Dec 23; 137(6):2146-57. PubMed ID: 19766644
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E, Darbalaei S, Dai A, Zhao P, Yang D, Sexton PM, Wang MW, Wootten D.
    Biochem Pharmacol; 2020 Jul 23; 177():114001. PubMed ID: 32360365
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.